
Drug Approvals
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.